Heartflow (NASDAQ:HTFL) Shares Down 5.2% After Earnings Miss

Heartflow, Inc. (NASDAQ:HTFL) shares dropped 5.2% during trading on Monday following a dissappointing earnings announcement. The company traded as low as $31.16 and last traded at $31.16. Approximately 128,436 shares changed hands during trading, a decline of 75% from the average daily volume of 508,908 shares. The stock had previously closed at $32.88.

The company reported ($1.46) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($1.26). The business had revenue of $43.42 million for the quarter, compared to analysts’ expectations of $43.20 million.

Wall Street Analyst Weigh In

HTFL has been the topic of several research analyst reports. Morgan Stanley initiated coverage on shares of Heartflow in a research report on Tuesday, September 2nd. They set an “equal weight” rating and a $35.00 price objective on the stock. Canaccord Genuity Group lifted their price objective on shares of Heartflow from $35.00 to $39.00 and gave the stock a “buy” rating in a research report on Monday. Zacks Research upgraded shares of Heartflow to a “hold” rating in a research report on Wednesday, September 3rd. JPMorgan Chase & Co. initiated coverage on shares of Heartflow in a research report on Tuesday, September 2nd. They set an “overweight” rating and a $36.00 price objective on the stock. Finally, Stifel Nicolaus initiated coverage on shares of Heartflow in a research report on Tuesday, September 2nd. They set a “buy” rating and a $35.00 price objective on the stock. Four investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $36.60.

Heartflow Price Performance

About Heartflow

We have pioneered the use of software and AI to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide. As of March 31, 2025, our Heartflow Platform has been used to assess CAD in more than 400,000 patients, including 132,000 in 2024 alone.